Lakefront completes sale of preclinical CAR — T programs to Armed Cell Therapeutics
Lakefront Biotherapeutics completed the sale of its preclinical cell therapy pipeline to Belgium-based Armed Cell Therapeutics on October 14, 2026. Terms include an upfront payment of €8 million, potential milestone payments of up to $230 million and a low-single-digit royalty. The transferred assets include multi-targ